Vedolizumab therapy is ineffective for primary sclerosing cholangitis in patients with inflammatory bowel disease: A GETAID multicentre cohort study.
Fiche publication
Date publication
mai 2019
Journal
Journal of Crohn's & colitis
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BRONOWICKI Jean-Pierre, Dr VUITTON Lucine, Pr PEYRIN-BIROULET Laurent, Pr REIMUND Jean-Marie
Tous les auteurs :
Caron B, Peyrin-Biroulet L, Pariente B, Bouhnik Y, Seksik P, Bouguen G, Caillo L, Laharie D, Carbonnel F, Altwegg R, Reenaers C, Serrero M, Trang-Poisson C, Nancey S, Filippi J, Abitbol V, Savoye G, Vuitton L, Viennot S, Fumery M, Reymond M, Bronowicki JP, Reimund JM, Amiot A,
Lien Pubmed
Résumé
Whether vedolizumab may be effective as a treatment for primary sclerosing cholangitis (PSC) in patients with inflammatory bowel disease (IBD) remains controversial.
Mots clés
Crohn’s disease, inflammatory bowel disease, primary sclerosing cholangitis, ulcerative colitis, vedolizumab
Référence
J Crohns Colitis. 2019 May 6;: